BR112018067485A2 - sistema para tratamento por termoterapia ou prevenção de infecções resistentes a antimicrobianos ou por biofilme - Google Patents

sistema para tratamento por termoterapia ou prevenção de infecções resistentes a antimicrobianos ou por biofilme

Info

Publication number
BR112018067485A2
BR112018067485A2 BR112018067485-0A BR112018067485A BR112018067485A2 BR 112018067485 A2 BR112018067485 A2 BR 112018067485A2 BR 112018067485 A BR112018067485 A BR 112018067485A BR 112018067485 A2 BR112018067485 A2 BR 112018067485A2
Authority
BR
Brazil
Prior art keywords
metal core
npa
thermotherapy
antimicrobial
prevention
Prior art date
Application number
BR112018067485-0A
Other languages
English (en)
Inventor
Gavalda Santapau Joan
Franco Puntes Victor
Torrents Serra Eduard
Original Assignee
Fundacio Hospital Universitari Vall D'hebron-Institut De Recerca
Fundacio Institut De Bioenginyeria De Catalunya
Institucio Catalana De Recerca I Estudis Avancats
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Hospital Universitari Vall D'hebron-Institut De Recerca, Fundacio Institut De Bioenginyeria De Catalunya, Institucio Catalana De Recerca I Estudis Avancats filed Critical Fundacio Hospital Universitari Vall D'hebron-Institut De Recerca
Publication of BR112018067485A2 publication Critical patent/BR112018067485A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0624—Apparatus adapted for a specific treatment for eliminating microbes, germs, bacteria on or in the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00—Ultrasound therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00—Ultrasound therapy
    • A61N7/02—Localised ultrasound hyperthermia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Ceramic Engineering (AREA)
  • Organic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

o sistema compreende um suporte para receber um conjunto de nanopartículas (npa) e para ser transportado para uma área localizada de um organismo infectado ou em risco de ser infectado por micro-organismos; o dito conjunto de nanopartículas (npa) compreendendo uma pluralidade de nanopartículas (nps), cada uma (np) tendo um núcleo de metal e uma superfície em torno do dito núcleo de metal, o núcleo de metal é reativo à energia térmica; e uma unidade de energia (15) configurada para aplicar pelo menos um disparo térmico na dita área localizada exposta ao conjunto de nanopartículas, aumentando a temperatura da dita área localizada através do conjunto de nanopartículas (npa), permitindo assim uma terapia antimicrobiana multimodal nanoteranóstica, em que o núcleo de metal sendo feito de prata, ouro, ferro ou uma mistura de prata e ouro.
BR112018067485-0A 2016-03-01 2017-03-01 sistema para tratamento por termoterapia ou prevenção de infecções resistentes a antimicrobianos ou por biofilme BR112018067485A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662301946P 2016-03-01 2016-03-01
US62/301,946 2016-03-01
PCT/IB2017/000186 WO2017149378A1 (en) 2016-03-01 2017-03-01 System for thermotherapy treatment or prevention of antimicrobial resistant or biofilm infections

Publications (1)

Publication Number Publication Date
BR112018067485A2 true BR112018067485A2 (pt) 2019-02-12

Family

ID=58489028

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018067485-0A BR112018067485A2 (pt) 2016-03-01 2017-03-01 sistema para tratamento por termoterapia ou prevenção de infecções resistentes a antimicrobianos ou por biofilme

Country Status (8)

Country Link
US (1) US10894085B2 (pt)
EP (1) EP3423098B1 (pt)
JP (1) JP2019512479A (pt)
AU (1) AU2017225481A1 (pt)
BR (1) BR112018067485A2 (pt)
CA (1) CA3016012A1 (pt)
ES (1) ES2808996T3 (pt)
WO (1) WO2017149378A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108815519B (zh) * 2018-05-07 2021-04-20 江苏大学 一种银纳米纤维光热剂的制备方法及用途
CN108721619B (zh) * 2018-06-07 2021-04-27 福建师范大学 热休克提高氨基糖苷类抗生素杀灭革兰氏阴性菌的方法
CN109200481A (zh) * 2018-08-24 2019-01-15 济南银中容和堂药业有限公司 一种医用量子照射管
MX2020004121A (es) * 2020-04-21 2022-01-14 Herman Diaz Arias "equipo para la destruccion de viruses mediante radiacion complementaria".
EP4149607A4 (en) * 2020-05-13 2024-07-31 The Trustees of Indiana University USE OF AN ELECTRIC CURRENT OR FIELD TO MANAGE THE RISK OF INFECTION BY ANTIMICROBIAL-RESISTANT MICROORGANISMS
ES1274434Y (es) * 2020-10-15 2021-10-19 Fundacio Hospital Univ Vall Dhebron Institut De Recerca Sistema de prevencion de formacion de biopelicula para dispositivos medicos respiratorios.
EP4019056A1 (en) * 2020-12-23 2022-06-29 Universitat Politècnica De Catalunya Method to produce in situ self-assembled multifunctional nanocomposite hydrogel and its uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006244A2 (en) * 1998-07-30 2000-02-10 Hainfeld James F Loading metal particles into cell membrane vesicles and metal particle use for imaging and therapy
US9393396B2 (en) 2002-02-14 2016-07-19 Gholam A. Peyman Method and composition for hyperthermally treating cells
JP2007509981A (ja) * 2003-10-31 2007-04-19 テバ ファーマシューティカル インダストリーズ リミティド 薬物デリバリー用ナノ粒子
US7999161B2 (en) 2005-01-22 2011-08-16 Alexander Oraevsky Laser-activated nanothermolysis of cells
US9034380B2 (en) 2005-08-04 2015-05-19 Midatech Ltd. Nanoparticles comprising antibacterial ligands
US20080213189A1 (en) 2006-10-17 2008-09-04 The Board Of Trustees Of The Leland Stanford Junior University Multifunctional metal-graphite nanocrystals
US20110123452A1 (en) 2009-11-25 2011-05-26 Nanoprobes, Inc. Metal oligomers and polymers and their use in biology and medicine
US20130095039A1 (en) 2010-09-30 2013-04-18 The Board Of Trustees Of The University Of Illinois Nucleic acid-mediated shape control of nanoparticles
US8784895B2 (en) * 2011-03-15 2014-07-22 Northwestern University Multifunctional metal nanoparticles having a polydopamine-based surface and methods of making and using the same
US20150125533A1 (en) 2011-07-25 2015-05-07 American University In Cairo Single-domain antibodies and graphene coated magnetic metal nanoparticles conjugate and methods for using the same
US20140294909A1 (en) 2011-10-13 2014-10-02 The Johns Hopkins University Nanocomposites of gold and polymers
US8831358B1 (en) * 2011-11-21 2014-09-09 Google Inc. Evaluating image similarity
US20150072337A1 (en) 2012-01-17 2015-03-12 William Marsh Rice University Theranostic methods and systems for diagnosis and treatment of malaria
WO2015148726A1 (en) 2014-03-26 2015-10-01 Beth Israel Deaconess Medical Center, Inc. Activation of antimicrobial agents
WO2015157530A2 (en) * 2014-04-09 2015-10-15 Brandeis University Enzymatically responsive magnetic particles and their use
US20180228942A1 (en) 2015-08-11 2018-08-16 Ptt Holding Aps A delivery device

Also Published As

Publication number Publication date
EP3423098B1 (en) 2020-05-06
EP3423098A1 (en) 2019-01-09
US20190054172A1 (en) 2019-02-21
JP2019512479A (ja) 2019-05-16
WO2017149378A1 (en) 2017-09-08
CA3016012A1 (en) 2017-09-08
ES2808996T3 (es) 2021-03-02
AU2017225481A1 (en) 2018-09-13
US10894085B2 (en) 2021-01-19

Similar Documents

Publication Publication Date Title
BR112018067485A2 (pt) sistema para tratamento por termoterapia ou prevenção de infecções resistentes a antimicrobianos ou por biofilme
BR112018013778A2 (pt) forno de indução e método para realização de um tratamento térmico de uma peça de reposição dental
EA201792509A1 (ru) Лечение рака
BR112014011830A2 (pt) dispositivos médicos de eluição
BR112018012499A2 (pt) método de tratamento térmico de um item não metálico ou metálico
EP3379897A4 (en) HEATING ELECTRICAL EQUIPMENT, ELECTRIC HEATING GLASS, HEAT-PRODUCING PLATE, VEHICLE, WINDOW FOR A BUILDING, BOW WITH LADDER, CONDUCTIVE SAMPLE BOW, CONDUCTIVE HEAT-GENERATING BODY, COMPOSITE GLASS, AND MANUFACTURING METHOD FOR THE CONDUCTIVE HEAT-GENERATING BODY
NI202000052A (es) Terapia de combinación para tratar o prevenir el cáncer
CL2019001717A1 (es) Anticuerpos contra el lif y usos de los mismos.
ECSP23081501A (es) Receptores quiméricos dirigidos a adgre2 y/o clec12a y usos de estos
BR112019005166A2 (pt) terapia de combinação com oligonucleotídeos antisense lipossômicos
ECSP23091984A (es) Compuestos y usos de estos
MA43294A1 (fr) Sels et promédicaments de 1-méthyl -d-tryptophane
BR102017004415A8 (pt) Máquina e processo de curvatura de uma canalização cilíndrica longitudinal
BR112018016398A2 (pt) métodos para o uso de 5'-adenosina difosfato ribose (adpr)
BR112018067967A2 (pt) tratamento de pacientes com hipercolesterolemia familiar homozigótica por meio de terapia hipolipemiante
FI20116029A0 (fi) Lämmönsiirtotela ja lämmönsiirtotelan valmistusmenetelmä
CO2018011200A2 (es) Marcador para predecir la respuesta al tratamiento del agente anticancerígeno en pacientes con cáncer
BR112018075488A2 (pt) tratamento térmico de sólidos de material irradiado com o uso de líquido de transferência de calor
BRPI0205207B1 (pt) forno de processo com aquecimento duplo provido de sistema de suportação de tubos de fornos com colunas de sustentação bi-pivotadas.
MX2019008562A (es) Productos laminados de cristal, termicamente aislantes, con una capa de revestimiento no uniforme y una pluralidad de cavidades selladas de moleculas de gas.
BR112019001348A2 (pt) processo para fornecer terapia protetora a tecidos ou fluidos biológicos
BR112019000124A2 (pt) método para o pré-aquecimento de um fluido a montante de um forno
BR112017028381A2 (pt) agente para melhora da hiperatividade do músculo detrusor com contratilidade prejudicada
EA201890599A1 (ru) Способ повышения безопасности и эффективности противораковой терапии
WO2020040706A3 (en) Disinfection apparatus and method of treating waste

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements